Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > nsclc > chemotherapy > topics & issues

Topics & Issues in NSCLC Chemotherapy

Chemotherapy vs. Best Supportive Care?
Duration of Chemotherapy
Post-Surgical (Adjuvant) Chemotherapy
Platinum vs. Non-platinum Regimens?
Chemotherapy Regimens: How Many Drugs?
Chemotherapy Sequence & Response

Chemotherapy vs. Best Supportive Care

Chemotherapy vs. Best Supportive Care - Recent MEDLINE Abstracts

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients with NSCLC Previously Treated with Platinum-based Chemotherapy (Journal of Clinical Oncology)
Abstract of a Journal of Clinical Oncology article (May 2000) reporting results of a study that found treatment with docetaxel is associated with significant prolongation of survival when compared to best supportive care in patients with NSCLC who had previously been treated with platinum-based chemotherapy. [5/00]



Duration of Chemotherapy

Phase III Trial Comparing a Defined Duration of Therapy versus Continuous Therapy Followed by Second-Line Therapy in Advanced - Stage IIIB/IV NSCLC (PubMed Abstract)
Reports on a study published in the 3/01/02 issue of the Journal of Clinical Oncology that compares four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced NSCLC. The study showed no overall benefit in survival, response rates, or QOL to continuing treatment with carboplatin/paclitaxel beyond four cycles in advanced NSCLC. [3/02]

Chemotherapy and Advanced Lung Cancer: Less Treatment May Be Enough
(NCI's cancer.gov)
Reports on a study published in the 3/01/01 issue of the Journal of Clinical Oncology that indicates three rounds of chemotherapy may offer the same benefit to NSCLC patients as six or more. [3/01]



Post-Surgical (Adjuvant) Chemotherapy

Adding Chemotherapy to Radiation After Surgery Adds No Benefit in Lung Cancer (NCI's cancer.gov)
Reports on a study published in the 10/26/00 issue of the New England Journal of Medicine that found adding chemotherapy to radiation therapy does not prolong survival in operable NSCLC. The large, randomized study compared the chemotherapy (cisplatin and etoposide) and radiation combination to radiation alone. Patients receiving the combined treatment had a median survival of 38 months compared to 39 months among those receiving radiation alone. Overall survival and recurrence rates were also similar in the two groups. [10/00]



Platinum vs. Non-platinum Regimens?

Platinum-based vs. Non-Platinum-based Chemotherapy in Advanced NSCLC: A Meta-Analysis of the Published Literature (PubMed)
Describes a meta-analysis performed to compare the activity, efficacy and toxicity of platinum-based vs. non-platinum based chemotherapy in patients with advanced NSCLC. Concludes that response is significantly higher with platinum-containing regimens. One-year survival was not significantly prolonged when platinum-based therapies were compared with third-generation-based combination regimens. Toxicity is generally higher for platinum-based regimens. [2/05]



Chemotherapy Regimens: How Many Drugs?

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced NSCLC? (PubMed)
Meta-analysis published in the July 28, 2004 issue of JAMA that examined whether adding a drug to a single-agent or to a 2-agent regimen increased tumor response rate, survival and toxicity. Data from all randomized controlled trials conducted from 1980 through 2001 comparing a doublet regimen with a single-agent regimen or comparing a triplet regimen with a doublet regimen in patients with advanced NSCLC were examined. The study concluded that adding a second drug improved tumor response and survival rate. Adding a third drug had a weaker effect on tumor response and no effect on survival. [7/04]



Chemotherapy Sequence & Response

Randomized Phase II Study of Two Opposite Administration Sequences of Irinotecan & Cisplatin In Patients with NSCLC
Abstract of a study published in the February 2006 issue of Cancer that found treatment with cisplatin followed by irinotecan appears to achieve better outcome in patients with NSCLC than does treatment with the same drugs in the reverse order. [02/06]



 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 27-Apr-2011
Karen Parles, MLS Editor